AMGN · 10-Q · 2026Q2

AMGEN INC

Filed 2026-08-05 · Healthcare · View original filing on EDGAR

Ranked Events

• Competition and Pricing PressureImportance 76 · Surprise 56
  Prolia sales declined 32% to $1,122 million in the quarter and 33% to $1,486 million for the six months ended June 30, 2026, driven by lower volume and net selling price. Prolia volume declined 20% quarterly and 19%…
• Capital Expenditures ProgramImportance 71 · Surprise 82
  Amgen’s capital expenditures were $1.2 billion in the six months ended June 30, 2026, compared with $780 million in the prior-year period, primarily for new plants and manufacturing-capacity expansion. Management…
• Liquidity and Debt PositionImportance 69 · Surprise 50
  Cash and cash equivalents increased to $13.989 billion at June 30, 2026 from $9.129 billion at December 31, 2025. Total debt was $57.304 billion, consisting of $5.445 billion of current debt and $51.859 billion of…
• Operating Income and MarginsImportance 69 · Surprise 64
  Second-quarter 2026 operating income increased 32.3% year over year to $3.514 billion from $2.656 billion, lifting operating margin to approximately 35.0% from 28.9%. Six-month operating income increased 61.2% to…
• Drug Pricing Policy ImpactImportance 66 · Surprise 74
  The Inflation Reduction Act (IRA) and expanded use of the 340B Program have negatively affected Amgen and are expected to continue affecting access, pricing, reimbursement and sales. CMS selected ENBREL for Medicare…
• IRS Tax DisputesImportance 65 · Surprise 60
  Amgen is contesting IRS notices concerning the allocation of profits between U.S. entities and entities in the U.S. territory of Puerto Rico. The 2010–2012 notices could produce approximately $3.6 billion of additional…
• Reimbursement and Payer MixImportance 65 · Surprise 60
  The Inflation Reduction Act selected Otezla for Medicare price setting beginning January 1, 2027. The earlier-than-anticipated selection reduced estimated future U.S. cash flows for Otezla and triggered an impairment…
• Operating Cash Flow TrendsImportance 63 · Surprise 64
  Net cash provided by operating activities increased to $6.191 billion in the six months ended June 30, 2026 from $3.671 billion in the prior-year period. The $2.520 billion increase primarily reflected the absence of…
• Market Demand TrendsImportance 58 · Surprise 56
  Global BLINCYTO sales increased primarily through volume growth, including 16% volume growth in the second quarter of 2026 and six-month growth driven by volume. Nplate sales increased 23% globally in the first half,…
• Regulatory Approval MilestonesImportance 57 · Surprise 60
  On April 27, 2026, FDA’s Center for Drug Evaluation and Research proposed withdrawing approval of TAVNEOS in the United States. The proposal followed a March 2026 Drug Safety Communication concerning serious, including…
• Operating Expense TrendsImportance 57 · Surprise 50
  Total operating expenses decreased 7% to $12.492 billion in the six months ended June 30, 2026, primarily because prior-year expenses included an $800 million Otezla intangible-asset impairment charge. Cost of sales…
• Guidance and OutlookImportance 56 · Surprise 42
  For the remainder of 2026, Amgen expects volume growth from certain brands to be partially offset by net selling-price declines. Management identifies potential MFN pricing reforms, tariffs, trade-protection measures,…
• IRS Tax ExaminationsImportance 53 · Surprise 60
  The IRS is examining Amgen’s tax years 2016–2018 and issued substantially similar draft notices of proposed adjustment in April, May and July 2026. The proposed adjustments concern profit allocation between the United…
• Revenue Performance and MixImportance 52 · Surprise 56
  Global Nplate sales increased 23% in the six months ended June 30, 2026, including a $60 million U.S. government order; excluding that order, sales increased 15%, driven by 11% volume growth and higher net selling…
• Income Tax Rate ChangesImportance 45 · Surprise 64
  The effective tax rate increased to 14.2% from 8.7% for the second quarter and to 13.6% from 10.7% for the first six months of 2026. The increases primarily reflected a change in earnings mix, including lower…
• Stock Repurchase ProgramImportance 44 · Surprise 24
  Amgen did not repurchase shares under its stock repurchase program during the six months ended June 30, 2026 or the comparable 2025 period. The company had $6.8 billion of remaining repurchase authorization at June 30,…
• Geographic Market CommentaryImportance 43 · Surprise 32
  Demand growth was broad-based geographically, with second-quarter volume increasing 9% in the U.S. and 8% in ROW. For the first six months, ROW volume growth of 10% exceeded U.S. growth of 9%. Growth in both regions…
• Quarterly Dividend DeclarationImportance 42 · Surprise 14
  Amgen declared quarterly cash dividends of $2.52 per share for the first, second and third quarters of 2026, representing a 6% increase over the comparable prior-year periods. Dividend payments totaled $2.7 billion…
• Trade Policy and TariffsImportance 40 · Surprise 42
  The United States and other countries have proposed or implemented numerous tariffs and trade-protection measures, including potential sector-specific tariffs on pharmaceuticals. In April 2026, the U.S. Administration…
• Product Pipeline ProgressImportance 38 · Surprise 60
  In June 2026, the European Commission granted marketing authorization for IMDYLLTRA as monotherapy for adults with extensive-stage small cell lung cancer. The authorization covers patients requiring systemic therapy…

Revenue by Product (in millions)

Revenue by Geography (in millions)